{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:27:49Z","timestamp":1773322069181,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xkme.2025.101115","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:41:42Z","timestamp":1758616902000},"page":"101115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study"],"prefix":"10.1016","volume":"7","author":[{"given":"John C.","family":"Lieske","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap W.","family":"Groothoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaacov","family":"Frishberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander F.","family":"Garrelfs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn S.","family":"Milliner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniella","family":"Magen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadas","family":"Shasha-Lavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevcan","family":"Bakkalo\u01e7lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Devresse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Cytter-Kuint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshad","family":"Kajbaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Gansner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xkme.2025.101115_bib1","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s40265-022-01735-x","article-title":"Improving treatment options for primary hyperoxaluria","volume":"82","author":"Hoppe","year":"2022","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.xkme.2025.101115_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2025.101115_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00240-023-01494-8","article-title":"Case series and literature review of primary hyperoxaluria type 1 in Chinese patients","volume":"51","author":"Wu","year":"2023","journal-title":"Urolithiasis"},{"issue":"10","key":"10.1016\/j.xkme.2025.101115_bib4","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s00467-021-05002-1","article-title":"Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study","volume":"36","author":"Ben-Shalom","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2025.101115_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nephro.2016.08.002","article-title":"Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center","volume":"13","author":"Soliman","year":"2017","journal-title":"N\u00e9phrol Ther"},{"issue":"5","key":"10.1016\/j.xkme.2025.101115_bib6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2025.101115_bib7","first-page":"1891","article-title":"Clinical manifestations of systemic oxalosis in primary hyperoxaluria type 1: when do which clinical manifestations occur [abstract PO-394]","volume":"31","author":"Garrelfs","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2025.101115_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11832-008-0082-4","article-title":"Skeletal features of primary hyperoxaluria type 1, revisited","volume":"2","author":"El Hage","year":"2008","journal-title":"J Child Orthop"},{"issue":"11","key":"10.1016\/j.xkme.2025.101115_bib9","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1253\/circj.CJ-10-0107","article-title":"Cardiac abnormalities in primary hyperoxaluria","volume":"74","author":"Mookadam","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.xkme.2025.101115_bib10","article-title":"Natural history of clinical, laboratory, and echocardiographic parameters of a primary hyperoxaluria cohort on long term hemodialysis","volume":"8","author":"Sas","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.xkme.2025.101115_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1046\/j.1523-1755.1999.00546.x","article-title":"Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure","volume":"56","author":"Hoppe","year":"1999","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.xkme.2025.101115_bib12","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/ndt\/8.12.1333","article-title":"Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria","volume":"8","author":"Marangella","year":"1993","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.xkme.2025.101115_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2025.101115_bib14","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/j.1600-6143.2010.03271.x","article-title":"Transplantation outcomes in primary hyperoxaluria","volume":"10","author":"Bergstralh","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.xkme.2025.101115_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000086359","article-title":"A 20-year experience of combined liver\/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984-2004","volume":"25","author":"Jamieson","year":"2005","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1016\/j.xkme.2025.101115_bib16","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ekir.2020.09.022","article-title":"Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives","volume":"5","author":"Devresse","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.xkme.2025.101115_bib17","series-title":"Package insert","year":"2022"},{"key":"10.1016\/j.xkme.2025.101115_bib18","series-title":"Summary of product characteristics","year":"2022"},{"issue":"7","key":"10.1016\/j.xkme.2025.101115_bib19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"13","key":"10.1016\/j.xkme.2025.101115_bib20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.xkme.2025.101115_bib21","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.ekir.2024.04.048","article-title":"Efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1: results from a phase III clinical trial","volume":"9","author":"Saland","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.xkme.2025.101115_bib22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.xkme.2025.101115_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.xkme.2025.101115_bib24","series-title":"Efficacy and safety of Lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial [abstract]","author":"Michael","year":"2022"},{"key":"10.1016\/j.xkme.2025.101115_bib25","series-title":"Package insert","year":"2025"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2025.101115_bib26","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/ckj\/sfab203","article-title":"Primary hyperoxaluria type 1 in developing countries: novel challenges in a new therapeutic era","volume":"15","author":"Soliman","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.xkme.2025.101115_bib27","first-page":"1","article-title":"2012 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2025.101115_bib28","article-title":"Development of an X-ray-based bone oxalosis grading scale to assess oxalate accumulation in patients with primary hyperoxaluria type 1","volume":"38","author":"Baker","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.xkme.2025.101115_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/j.ajkd.2025.01.016","article-title":"Efficacy and safety of lumasiran for advanced primary hyperoxaluria type 1: 24-month follow-up of the phase 3 ILLUMINATE-C trial","volume":"86","author":"Sellier-Leclerc","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.xkme.2025.101115_bib30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.xkme.2025.101115_bib31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.xkme.2025.101115_bib36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ki.2014.222","article-title":"Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type","volume":"86","author":"Mandrile","year":"2014","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2025.101115_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.ajkd.2022.01.428","article-title":"Estimated GFR slope across CKD stages in primary hyperoxaluria type 1","volume":"80","author":"Singh","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.xkme.2025.101115_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/nep.14273","article-title":"Comprehensive evaluation of patients with primary hyperoxaluria type 1: a nationwide study","volume":"29","author":"Bakkalo\u011flu","year":"2024","journal-title":"Nephrology (Carlton)"},{"issue":"12","key":"10.1016\/j.xkme.2025.101115_bib34","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1007\/s00467-019-04330-7","article-title":"Subclinical myocardial disease in patients with primary hyperoxaluria and preserved left ventricular ejection fraction: a two-dimensional speckle-tracking imaging study","volume":"34","author":"Lagies","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2025.101115_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000086360","article-title":"International registry for primary hyperoxaluria","volume":"25","author":"Lieske","year":"2005","journal-title":"Am J Nephrol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:47:27Z","timestamp":1773262047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525001517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2590059525001517"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101115","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101115"}}